Current Report Filing (8-k)
August 17 2018 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): August 13, 2018
Amedica
Corporation
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-33624
|
|
84-1375299
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1885
West 2100 South
Salt
Lake City, UT
|
|
84119
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (801) 839-3500
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
August 13, 2018, Amedica Corporation (“Amedica” or “the Company”) received a notice from the Nasdaq Listing
Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the bid
price of the Company’s common stock for the last 30 consecutive trading days had closed below the minimum $1.00 per share
required for continued listing under Listing Rule 5550(a)(2).
The
Nasdaq notification letter does not result in the immediate delisting of the Company’s common stock, and the stock will
continue to trade uninterrupted on the The Nasdaq Capital Market under the symbol “AMDA”.
If
the Company does not regain compliance with Rule 5550(a)(2) by February 11, 2019, the Company may be afforded a second 180 calendar
day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market
value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid
price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the
second compliance period, which may include, if necessary, implementing a reverse stock split.
The
Company intends to actively monitor the closing bid price for its common stock and will consider available options to resolve
the deficiency and regain compliance with Nasdaq Listing Rule 5550(a)(2).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMEDICA
CORPORATION
|
|
|
Date:
August 17, 2018
|
/s/
B Sonny Bal
|
|
B.
Sonny Bal
|
|
Chief
Executive Officer
|
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024